Bio-Path (NASDAQ:BPTH) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the stock.

Bio-Path Stock Performance

NASDAQ BPTH opened at $0.18 on Tuesday. The business’s fifty day simple moving average is $0.16 and its 200-day simple moving average is $0.56. Bio-Path has a 52 week low of $0.12 and a 52 week high of $4.55.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.